Indivior recently stated that a preliminary injunction in the US court against Dr. Reddy’s will remain in place in the US. The company will continue to pursue the infringement case against Dr. Reddy’s, delaying the launch of the latter’s generic.
Last month, the US Federal Court of Appeals granted Dr. Reddy’s Laboratories the right to sell its generic of Suboxone and overturned the preliminary injunction issued by Indivior.
Indivior immediately addressed the ruling by stating it would issue a petition to stay the preliminary injunction, which had resulted in a drop in share price by over 40%.
After last month’s ruling, and Indivior’s petition, Dr. Reddy’s filed a motion that requested the court to either issue a mandate, prohibiting the company from marketing the generic, or stay the preliminary injunction until a mandate is issued.
Suboxone film is an opioid use disorder treatment of buprenorphine and naloxone designed to dissolve under the tongue to help those from withdrawal symptoms.
The drug is proprietary to Indivior and is responsible for 80% of the company’s revenue, Dr. Reddy’s potential generic rival is set at a lower price point.
After the US Food and Drug Administration (FDA) approved the generic, Indivior expressed concerns regarding patent infringement.
With the most recent ruling, Dr. Reddy’s shares fell 6% on India’s National Stock Exchange, and Indivior’s rose 12% on the London Stock Exchange.
